2007's most comprehensive QT & Safety Pharmacology Strategy Congress takes place in just under two weeks!

Posted:
11
October 2007

The pre-conference workshop will be hosted by Richmond Pharmacology; the leading Trial Centre and ECG Core Lab for conducting QTc studies. The workshop will address 'Key Issues and Best Practice in Conducting a Definitive Thorough QTc Study'.Included in the line up of speakers will be Prof. A. J. Camm, Chairman of the Department of Cardiovascular Sciences and the Division of Cardiological Sciences, St George's Hospital, UK. This offers you the unique opportunity to discuss the latest developments in the design and conduct of QTc studies. Please click the following link to view the agenda for the meeting.As hosts of the QTc Workshop we are pleased to offer the Workshop at a discounted rate to our clients. Alternatively, we are able to also offer both the workshop and main conference for the reduced price of £250. For further information contact Charlotte Vowden at c.vowden@richmondpharmacology.com.

Latest news

Upcoming Event

The 41st Annual Scientific Meeting of the Japanese Society of Clinical Pharmacology and Therapeutics (JSCPT)

4 – 5 December 2020
The 41st Annual Scientific meeting focuses on international collaboration in the pursuit of drug discovery and drug development.
View event

Contributing to our community in 2020

December 17, 2020
Richmond Pharmacology has a long-standing tradition of supporting local, national, and international charities and 2020 is no exception.
Read more

Richmond Pharmacology supports Cardior Pharmaceuticals with the pioneering trial of an oligonucleotide-based drug in heart failure patients

December 14, 2020
Richmond Pharmacology is delighted to welcome the positive Phase Ib results of Cardior Pharmaceuticals lead compound CDR132L for heart failure.
Read more

Marking a milestone for gene editing

November 10, 2020
We are pleased to share that Richmond Pharmacology, in partnership with Intellia Therapeutics and the Royal Free Hospital, have treated the first patient in a landmark CRISPR/Cas9 clinical trial of NTLA-2001
Read more